Author: Jason Fieber, Dividends And Income

This is a high-quality company with near-term uncertainty but massive long-term potential. The company has excellent fundamentals, an exciting upcoming acquisition, and plenty of growth potential. Today, shares are potentially 28% undervalued and paying a 4%-plus yield…

With this company, you have strong revenue, profit, and dividend growth — with the dividend supported by a moderate payout ratio. The balance sheet isn’t overly leveraged and profitability is impressive. That said, we might expect the stock to be priced at a premium, to go along with its premium quality. But the stock actually looks cheap here — potentially 17% undervalued…

This is a high-quality and growing firm with a blockbuster drug in its arsenal. It’s growing well above average, it pays a 3.8% yield, and it’s potentially 29% undervalued…

This appears to be one of the more interesting and undervalued dividend growth stocks available at this time, and it’s absolutely worth a good look right now…